Why testosterone keeps declining — causes, rising estrogen, and what the data says actually works.

The data: four cohorts, same signal

The testosterone decline story starts with a 2007 paper out of the Boston-area Massachusetts Male Aging Study.^[1] Researchers tracked 1,532 men across three survey waves between 1987 and 2004. The finding was stark: testosterone was declining at the population level at roughly 1% per year — not because of aging, but on top of aging. A 65-year-old man in 1987 had significantly higher testosterone than a 65-year-old man in 2002. Same age. Different cohort. Lower levels.

That study is the most-cited reference on this topic, but it is not alone. A Finnish cohort that analyzed 3,271 men across survey waves from 1972 to 2002 found even more dramatic numbers: men aged 60–69 born in 1942–1951 had testosterone of 13.8 nmol/L, compared to 21.9 nmol/L in men of the same age born in 1913–1922 — a 37% drop across birth cohorts.^[2] This held after body mass index (BMI) adjustment. The Danish Health and Morbidity Survey, which analyzed 5,350 male serum samples from 1982 to 2001, found the same secular downward trend in testosterone and sex hormone-binding globulin (SHBG — the protein that transports testosterone in the blood) independent of age.^[3]

The most recent large dataset comes from Israel: 102,334 men measured between 2006 and 2019, confirming that the age-independent decline has continued into the 2010s — and that rising obesity rates do not fully account for it.^[4]

The convergence of four independent longitudinal cohorts across different countries, decades, and methodologies points to something real. This is not measurement error. It is not reverse causation. It is a population-level signal with no single, fully established cause. What the data does support is a cluster of converging pressures — and that framing matters, because addressing any one of them in isolation underdelivers.

Obesity and aromatase — the conversion engine

The most mechanistically well-understood driver of low testosterone in contemporary men is the interaction between fat mass and aromatase. Aromatase is an enzyme that converts androgens — including testosterone — into estrogens. It is expressed throughout the body, but adipose (fat) tissue is a major production site. The more fat a man carries, particularly visceral and subcutaneous abdominal fat, the more aromatase is active, and the more testosterone gets converted to estradiol (E2) — the primary estrogen.^[5]

This creates a self-reinforcing cycle. Higher estrogen in men suppresses the hypothalamic-pituitary-gonadal (HPG) axis — the hormonal signaling chain that tells the testes to produce testosterone — via negative feedback. The pituitary reads circulating estrogen as a signal to reduce luteinizing hormone (LH) output, which in turn reduces testicular testosterone production. So more fat drives more aromatase, which drives more estrogen, which suppresses the signal to make testosterone, which reduces testosterone, which promotes fat storage. The cycle compounds.

The reversal evidence is compelling. A 2013 trial put 13 severely obese men (median BMI 42.7) on an 800 kcal/day protocol for twelve weeks. Total testosterone nearly doubled: from 6.97 to 13.21 nmol/L.^[6] The mechanisms were dual: improved testicular function and reduced testosterone-to-estradiol conversion via reduced aromatase activity. This is not a supplement study. It is direct evidence that the fat-aromatase cycle is reversible — and that weight loss is the single most powerful testosterone intervention for men who are carrying excess body fat.

The broader obesity trend since the 1970s tracks exactly with the testosterone decline. That is not coincidence. But as the Israeli cohort showed, it does not fully explain the numbers — which points to additional drivers.

Endocrine disruptors: BPA, phthalates, and PFAS

Endocrine-disrupting chemicals (EDCs) are compounds that interfere with hormone signaling — some by binding estrogen receptors directly, others by blocking androgen receptors, others by impairing steroidogenesis at the Leydig cells in the testes. Three categories have the strongest human evidence: bisphenols, phthalates, and per- and polyfluoroalkyl substances (PFAS — often called "forever chemicals").

A case-control study of 163 men from Belgian fertility clinics found that urinary BPA correlated negatively with testosterone levels, and that phthalate metabolites were associated with lower inhibin B and elevated LH — a pattern consistent with primary testicular dysfunction.^[7] Men with higher overall EDC body burden had approximately twice the odds of subfertility. These are correlation data, but the biological mechanism is established: BPA binds estrogen receptors with meaningful affinity, and certain phthalates directly impair Leydig cell steroidogenesis in animal models.

The PFAS data is newer and more concerning. A 2021 study of 902 men measuring 24 targeted PFAS found that the PFAS mixture was significantly and inversely associated with estradiol levels, and that certain long-chain PFAS — specifically PFTrDA and PFDoA — were inversely associated with insulin-like factor 3 (INSL3), a direct biomarker of Leydig cell function that is not influenced by the HPG axis in the same way testosterone is.^[8] Impaired INSL3 means the testes themselves are being compromised at the cellular level, not just suppressed by upstream signaling.

These chemicals have proliferated since the 1940s. They are in food packaging, non-stick cookware, waterproof clothing, firefighting foam, and the water supply of many municipalities. Body burden has been rising. The practical signal is not that any single exposure is catastrophic, but that the cumulative load matters — and that reducing it where practical is worthwhile.

Actionable reduction without paranoia: glass or stainless food storage, cold or warm (not hot) plastic exposure to food, filtering drinking water with activated carbon or reverse osmosis where PFAS contamination is documented, and choosing products with explicit PFAS-free certification for items in long-term contact with skin or food.

Sleep deprivation and the HPG axis

Testosterone secretion follows a circadian pattern. Peak concentrations occur in the early morning, driven by pulsatile LH release during sleep — particularly during slow-wave and rapid eye movement (REM) sleep. When sleep is cut, that pulsatility is disrupted.

A randomized crossover trial published in Sleep in 2020 put 35 healthy men — both young and older — through total overnight sleep deprivation. The result: significant reductions across every testosterone parameter measured — mean concentration, basal secretion, total secretion, pulsatile secretion, and pulse frequency.^[9] The effects were most pronounced in older men, suggesting that the HPG axis becomes progressively less resilient to sleep disruption with age.

The broader picture is consistent. Studies of men who chronically sleep fewer than six hours per night show testosterone levels that track closer to men a decade older. Deep sleep also drives growth hormone release, and GH and testosterone are co-regulated — their production patterns reinforce each other. Getting to bed at a consistent time and protecting slow-wave sleep are not optional accessories for hormonal health. They are foundational inputs. No supplement stack repairs what chronic sleep deprivation costs.

Lifestyle interventions with actual evidence

Before discussing supplements or clinical options, the lifestyle levers deserve direct, non-hedged framing: they are the tier-one intervention. For most men, they are sufficient. For men with significantly compromised testosterone, they are prerequisite — clinical options work better on a foundation that is not actively fighting against them.

Resistance training. Heavy compound resistance exercise — squats, deadlifts, rows, presses — produces acute testosterone spikes and, over time, improves the hormonal milieu in ways that outlast any single session. Volume and intensity matter. Two to four sessions per week of progressive overload, not cardio-only, not light machines. The testes respond to the stress signal of heavy mechanical load.

Weight loss if indicated. As the aromatase data above shows, reducing fat mass is the most direct lever available. The caloric restriction trial that doubled testosterone in twelve weeks used a severe protocol, but the mechanistic path is proportional — fat loss at any pace reduces aromatase load and estrogen conversion. This is especially relevant given that obesity rates have risen in parallel with testosterone decline. Metabolic syndrome and low testosterone are bidirectionally linked; addressing one improves the other.

Stress management. Cortisol and testosterone are functionally antagonistic. Chronic psychosocial stress elevates cortisol, which suppresses GnRH (gonadotropin-releasing hormone) at the hypothalamus — reducing the entire downstream LH → testosterone cascade. There are no clean RCTs on stress reduction and testosterone in men, but the mechanism is well-established, the cortisol-testosterone inverse relationship is consistent in the literature, and stress reduction has no cost at the margins. It belongs in the protocol.

Alcohol reduction. Alcohol is directly gonadotoxic at even moderate-to-heavy intake — it impairs Leydig cell function, elevates aromatase activity in the liver, and disrupts sleep architecture. The dose-response relationship is unfavorable for men concerned about hormonal health. Occasional low-volume consumption is likely inconsequential; regular heavy drinking is not.

Supplements: what the RCTs show

The supplement space around testosterone is cluttered with overblown claims. A few compounds have real controlled trial data. The following are the ones worth considering — with the appropriate caveats stated clearly.

Zinc

The foundational zinc–testosterone paper is a 1996 study by Prasad and colleagues: dietary zinc restriction in young men reduced testosterone from 39.9 to 10.6 nmol/L over twenty weeks (p=0.005); zinc supplementation in zinc-deficient elderly men nearly doubled testosterone from 8.3 to 16.0 nmol/L (p=0.02).^[10] The critical caveat: zinc supplementation appears to restore testosterone when zinc status is deficient, not to elevate it above baseline in men who are replete. Western ultra-processed diets are progressively lower in dietary zinc, and the case for ensuring adequate intake — through diet or supplementation — is solid. The case for mega-dosing above sufficiency is not.

Vitamin D

Vitamin D receptors are expressed on Leydig cells — the testicular cells that produce testosterone — and the mechanistic link between vitamin D status and testosterone production has been plausible for over a decade. A 2023 RCT of 307 infertile men found that in men with vitamin D insufficiency (≤50 nmol/L), supplementation produced a significantly higher testosterone-to-LH ratio versus placebo — indicating improved Leydig cell efficiency per unit of stimulation.^[11] As with zinc, the benefit appears conditional on deficiency. Given that vitamin D insufficiency is extremely common in northern latitudes and in people who work predominantly indoors, baseline testing and correction is broadly warranted — not as a targeted testosterone intervention, but as basic physiological maintenance. See also what the vitamin D mortality data actually shows.

Ashwagandha (Withania somnifera)

Ashwagandha is an adaptogen — it pulls the stress signal down. The testosterone effect, where it exists, likely operates primarily through cortisol suppression. A 2019 double-blind crossover RCT of 50 overweight men aged 40–70 found that ashwagandha extract (standardized to 21 mg withanolide glycosides per day) produced a 14.7% greater increase in testosterone versus placebo over sixteen weeks (p=0.010), along with an 18% greater increase in dehydroepiandrosterone sulfate (DHEA-S — the androgen precursor).^[12] This is a real, well-controlled study in a relevant population. It is not dramatic, but it is meaningful — particularly for men whose testosterone is suppressed partly by chronic stress load.

Boron

Boron is the underappreciated entry in this category. A small but important 2011 pilot trial — 8 healthy men, 10 mg boron per day for seven days — found that SHBG decreased significantly within six hours of acute supplementation; after one week of daily dosing, mean free testosterone increased significantly and mean estradiol decreased significantly.^[13] The proposed mechanism is SHBG inhibition: by reducing SHBG, boron increases the fraction of testosterone that is biologically free and active, rather than bound and unavailable. The n=8 sample size is a real limitation; this is pilot-level evidence. But the mechanism is plausible, the signal is directionally clear, and the safety profile at 3–10 mg dietary supplementation is well-established. It warrants inclusion in a thoughtful protocol.

DIM (3,3′-diindolylmethane)

Diindolylmethane (DIM) is a compound derived from cruciferous vegetables that modulates estrogen metabolism in a directionally favorable way. A Phase I clinical study in patients with thyroid proliferative disease found that 300 mg/day of DIM for fourteen days shifted estrogen metabolism toward the 2-hydroxyestrone pathway — the metabolically inactive, anti-estrogenic direction — confirmed in urine and tissue samples.^[14] The population was thyroid disease patients, not generally healthy men, which limits direct extrapolation. This is not a testosterone-boosting intervention; it is an estrogen-clearing intervention. For men running elevated estradiol — particularly men who are overweight or who have high aromatase activity — reducing circulating estrogen load may reduce the HPG-axis suppression driving low testosterone. The logic is mechanistically sound. The RCT base for testosterone outcomes specifically is limited; use it as one tool in a stack, not as a primary intervention.

Clinical options: when lifestyle isn't enough

For men whose testosterone remains clinically low after six to twelve months of consistent lifestyle optimization, two clinical options are worth understanding. These require a prescribing clinician and baseline labs — not self-administration.

Enclomiphene citrate. Clomiphene is a selective estrogen receptor modulator (SERM) that blocks estrogen receptors at the hypothalamus and pituitary, reducing negative feedback and thereby increasing LH and FSH output — which stimulates endogenous testosterone production. Enclomiphene is the trans-isomer of clomiphene with a cleaner pharmacological profile. A Phase III RCT comparing enclomiphene to topical testosterone gel found that enclomiphene raised testosterone comparably to gel while preserving sperm counts — whereas testosterone replacement therapy (TRT) gel caused a marked spermatogenesis drop.^[15] This matters: men who want improved testosterone without sacrificing fertility should be discussing enclomiphene with a clinician, not starting TRT. See the full breakdown in the enclomiphene and HCG for testosterone support article.

Testosterone replacement therapy (TRT). TRT — injectable testosterone cypionate or enanthate, topical gel, pellets — is the most effective intervention for raising testosterone. It is also the most aggressive. It shuts down endogenous testosterone production almost entirely, suppresses spermatogenesis, requires indefinite continuation to maintain effect, and carries a side-effect profile that demands monitoring (hematocrit elevation, cardiovascular considerations, estradiol management). It is the right tool for men with true hypogonadism — clinically confirmed low testosterone with symptoms — who have not responded to other measures. It is not the right tool for men who want to optimize borderline-low testosterone without first addressing the upstream causes described in this article. The sequence matters.

References

1. Travison TG, Araujo AB, O'Donnell AB, Kupelian V, McKinlay JB. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab. 2007;92(1):196–202. doi:10.1210/jc.2006-1375
2. Perheentupa A, Mäkinen J, Laatikainen T, et al. A cohort effect on serum testosterone levels in Finnish men. Eur J Endocrinol. 2013;168(2):227–233. doi:10.1530/EJE-12-0288
3. Andersson AM, Jensen TK, Juul A, Petersen JH, Jørgensen T, Skakkebaek NE. Secular decline in male testosterone and sex hormone binding globulin serum levels in Danish population surveys. J Clin Endocrinol Metab. 2007;92(12):4696–4705. doi:10.1210/jc.2006-2633
4. Chodick G, Epstein S, Shalev V. Secular trends in testosterone — findings from a large state-mandate care provider. Reprod Biol Endocrinol. 2020;18(1):19. doi:10.1186/s12958-020-00575-2
5. Xu X, Sun M, Ye J, et al. The effect of aromatase on the reproductive function of obese males. Horm Metab Res. 2017;49(8):572–579. doi:10.1055/s-0043-107835
6. Schulte DM, Hahn M, Oberhäuser F, et al. Caloric restriction increases serum testosterone concentrations in obese male subjects by two distinct mechanisms. Horm Metab Res. 2014;46(1):42–45. doi:10.1055/s-0033-1358678
7. Den Hond E, Tournaye H, De Sutter P, et al. Human exposure to endocrine disrupting chemicals and fertility: a case-control study in male subfertility patients. Environ Int. 2015;84:154–160. doi:10.1016/j.envint.2015.07.017
8. Luo K, Liu X, Nian M, et al. Environmental exposure to per- and polyfluoroalkyl substances mixture and male reproductive hormones. Environ Int. 2021;150:106496. doi:10.1016/j.envint.2021.106496
9. Liu PY, Takahashi PY, Yang RJ, Iranmanesh A, Veldhuis JD. Age and time-of-day differences in the hypothalamo-pituitary-testicular, and adrenal, response to total overnight sleep deprivation. Sleep. 2020;43(7):zsaa008. doi:10.1093/sleep/zsaa008
10. Prasad AS, Mantzoros CS, Beck FW, Hess JW, Brewer GJ. Zinc status and serum testosterone levels of healthy adults. Nutrition. 1996;12(5):344–348. doi:10.1016/s0899-9007(96)80058-x
11. Holt R, Warming S, Jørgensen N, et al. Effects of vitamin D supplementation on testosterone concentrations in infertile men: results from a randomized double-blinded placebo-controlled trial. Andrology. 2023;11(8):1554–1562. doi:10.1111/andr.13505
12. Lopresti AL, Drummond PD, Smith SJ. A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of ashwagandha in aging, overweight males. Am J Mens Health. 2019;13(2):1557988319835985. doi:10.1177/1557988319835985
13. Naghii MR, Mofid M, Asgari AR, Hedayati M, Daneshpour MS. Comparative effects of daily and weekly boron supplementation on plasma steroid hormones and proinflammatory cytokines. J Trace Elem Med Biol. 2011;25(1):54–58. doi:10.1016/j.jtemb.2010.10.001
14. Rajoria S, Suriano R, Parmar PS, et al. 3,3′-diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: a pilot study. Thyroid. 2011;21(3):299–304. doi:10.1089/thy.2010.0245
15. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677–685. doi:10.1111/bju.13337